Using genetic testing to personalize treatment for PTSD in veterans
Personalized Pharmacotherapy Using Pharmacogenetics in Veterans Seeking Treatment for Mental Health
This study is testing if using genetic testing can help personalize mental health treatments for veterans and members of the Canadian Armed Forces and Royal Canadian Mounted Police with PTSD.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 155 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's Academic / other |
| Locations | 1 site (London, Ontario) |
| Trial ID | NCT06335043 on ClinicalTrials.gov |
What this trial studies
This observational clinical trial evaluates the effectiveness of pharmacogenetic testing (PGx) to tailor mental health treatments for veterans and members of the Canadian Armed Forces and Royal Canadian Mounted Police. Participants, including both psychiatrists and patients, will complete surveys to assess their knowledge and attitudes towards PGx. Patients can choose to opt-in for PGx-guided treatment, which involves sharing genetic test results with their psychiatrists to inform treatment planning. The study aims to gather insights on the integration of PGx in clinical practice and its impact on treatment outcomes.
Who should consider this trial
Good fit: Ideal candidates include veterans or current members of the CAF or RCMP who are patients at the London St. Joseph's OSI Clinic and have a current diagnosis of an operational stress injury.
Not a fit: Patients who are unable to provide informed consent or do not meet the eligibility criteria will not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could lead to more effective and personalized treatment options for veterans suffering from PTSD.
How similar studies have performed: While pharmacogenetic testing is a growing field, this specific application in PTSD treatment for veterans is relatively novel and has not been extensively tested in similar studies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria:
* Provider participant:
* Are at least 18 years of age;
* Speak and write English;
* Currently working as an OSI Clinic Psychiatrist at the London St. Joseph's OSI Clinic.
* Psychiatrist with an active caseload of patients being treated for OSIs.
* Patient participant:
* Veteran (patient) CAF or RCMP member;
* Are at least 18 years of age;
* Are a current patient at the London St. Joseph's OSI Clinic;
* Current diagnosis of an OSI;
* Speak and write English;
* Consents to the use of CROMIS data for the purpose of this study; and
* Consents to the use of prior OSI Clinic data for research purposes (if you have been a patient at the OSI Clinic prior to this study, the research team will use past OSI Clinic data to observe changes over time).
Exclusion Criteria:
* Participants (provider or patients) who are unable to, or do not, provide informed consent for participation.
Where this trial is running
London, Ontario
- MacDonald Franklin OSI Research and Innovation Centre — London, Ontario, Canada (Recruiting)
Study contacts
- Study coordinator: Natalie Ein, PhD
- Email: natalie.ein@sjhc.london.on.ca
- Phone: 416-573-9047
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.